Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H34O3 |
| Molecular Weight | 298.4608 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCC\C=C/CCCCCCC(O)C(O)=O
InChI
InChIKey=JBSOOFITVPOOSY-KTKRTIGZSA-N
InChI=1S/C18H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h9-10,17,19H,2-8,11-16H2,1H3,(H,20,21)/b10-9-
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
844021
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/11/916
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
||
|
NCI_THESAURUS |
C274
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00430863
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | |||
|
9796304
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | |||
|
11607
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | INN | ||
|
C105401
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | NCIT | ||
|
56472-29-8
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | |||
|
100000181927
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | |||
|
SUB195753
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | |||
|
MN-165
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | |||
|
143096
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | |||
|
2-HYDROXYOLEIC ACID
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY | Biochem/physiol Actions: 2OHOA induces cell cycle arrest and apoptosis in several cancer cell lines, including glioma, leukemia, breast and colon cancer lines. 2OHOA increases sphingomyelin (SM) levels in the membranes of tumor cells, which typically display decreased SM membrane content, and remodeled membranes, compared with normal cells. The compound has no effect on SM levels in non-cancer cells. | ||
|
OSV3KVO1BT
Created by
admin on Tue Apr 01 16:40:11 GMT 2025 , Edited by admin on Tue Apr 01 16:40:11 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
